This Core Support Center Grant (P30) application requests continued support for an analytic and synthetic chemistry laboratory and administrative shared core infrastructure. The participating, currently funded, constituent projects continue research programs with human laboratory and treatment clinic studies of the clinical pharmacology of abused drugs, pharmacotherapies and other treatment strategies to treat drug abuse and addictions. Drugs of interest to participating projects and assays available include nicotine and its metabolites, cocaine, methamphetamine and other phenethylamines, alcohol, MDMA, ephedra alkaloids, caffeine, gamma hydroxybutyrate (GHB), salvinorin, adenosine, and neurosteroids, and opiates. Analytical methods have been developed and validated in the core analytic laboratory to support studies with these drugs. Other new assays and labeled (deuterated) compounds will be made available to the associated research projects as needed. Disciplines represented by the participating projects and investigators include psychiatry, clinical psychology, neurology, general internal medicine, cardiology and clinical pharmacology, psychopharmacology, toxicology, genetics, pediatrics, pharmacy, organic, medicinal and analytical chemistry, and statistics.
Our aims are: (1) to provide a state-of-the-art well equipped and staffed, analytical and synthetic chemistry laboratory resource for the participating projects of drug abuse researchers at UCSF and at other institutions. (2) To provide administrative support for manuscript preparation, IRB and related regulatory documents, grants management, and other research administrative services of value participating projects. (3) To provide statistical consulting services regarding study design and data analysis strategies, particularly optimal pharmacokinetic analysis to participating projects. The overall objective is to provide sophisticated analytic laboratory resources with stability of support together with adequate administrative support responsive to the needs of individual funded constituent scientific projects as those projects change and evolve. This facility is a cost-effective shared laboratory resource that enhances and extends research possibilities of investigators currently funded by NIH or other federal or nonfederal sources to further our understanding of human psychoactive drug use, abuse and addiction, its health consequences and its treatment management.

Public Health Relevance

When researching the causes of drug addictions, measuring the health and other consequences of drug use, and searching for effective treatments for addicted people, measures of the amount of drug actually in a person's body are often important. This grant supports a state of the art analytic chemistry laboratory that provides, to a large number of research groups, innovative, sensitive, reliable and cost effective measures of commonly used drugs like nicotine, methamphetamine, opiates and other addicting drugs.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T (06))
Program Officer
Chiang, Nora
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Pulvers, Kim; Emami, Ashley S; Nollen, Nicole L et al. (2018) Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes. Nicotine Tob Res 20:206-214
Panzer, Ariane R; Lynch, Susan V; Langelier, Chaz et al. (2018) Lung Microbiota Is Related to Smoking Status and to Development of Acute Respiratory Distress Syndrome in Critically Ill Trauma Patients. Am J Respir Crit Care Med 197:621-631
Benowitz, Neal L; Flanagan, Christie A; Thomas, Timothy K et al. (2018) Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users. Int J Circumpolar Health 77:1528125
Vogel, Erin A; Ramo, Danielle E; Rubinstein, Mark L (2018) Prevalence and correlates of adolescents' e-cigarette use frequency and dependence. Drug Alcohol Depend 188:109-112
Rubinstein, Mark L; Delucchi, Kevin; Benowitz, Neal L et al. (2018) Adolescent Exposure to Toxic Volatile Organic Chemicals From E-Cigarettes. Pediatrics 141:
Benowitz, Neal L; Nardone, Natalie; Jain, Shonul et al. (2018) Comparison of Urine 4-(Methylnitrosamino)-1-(3)Pyridyl-1-Butanol and Cotinine for Assessment of Active and Passive Smoke Exposure in Urban Adolescents. Cancer Epidemiol Biomarkers Prev 27:254-261
St Helen, Gideon; Shahid, Marian; Chu, Sherman et al. (2018) Impact of e-liquid flavors on e-cigarette vaping behavior. Drug Alcohol Depend 189:42-48
Nabavizadeh, Pooneh; Liu, Jiangtao; Havel, Christopher M et al. (2018) Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. Tob Control 27:s13-s19
St Helen, Gideon; Jacob Iii, Peyton; Nardone, Natalie et al. (2018) IQOS: examination of Philip Morris International's claim of reduced exposure. Tob Control 27:s30-s36
Gubner, Noah R; Guydish, Joseph; Humfleet, Gary L et al. (2017) Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. Drug Alcohol Depend 178:267-270

Showing the most recent 10 out of 187 publications